1 treatment) and nasopharyngitis (once-weekly treatment) were
the most common adverse events.
2 Affect lability (11%) and sedation (9%) were
the most common adverse events.
3 nerally well tolerated, with fatigue, fevers, and chills as
the most common adverse events.
4 treated patients and were similar across treatment groups;
the most common adverse events (
300 mg intravenous zanamivir,
5 The most common adverse events (
AEs) were insomnia, fatigue,
6 The most common adverse events attributed to X-82 were diarrh
7 The most common adverse events for both groups were nasophary
8 The most common adverse events (&
gt;/=10%) in cariprazine-treate
9 The most common adverse events in both groups were gastrointe
10 The most common adverse events in both groups were headache a
11 The most common adverse events in both the simtuzumab and pla
12 The most common adverse events in the macitentan group were p
13 The most common adverse events in the opicapone vs placebo gr
14 The most common adverse events in this period were injection-
15 The most common adverse events included fatigue, headache, na
16 The most common adverse events of grade 3 or higher during tr
17 The most common adverse events of grade 3 or worse in the doc
18 The most common adverse events of grade 3 or worse severity w
19 The most common adverse events overall were upper respiratory
20 The most common adverse events reported in the re-treatment A
21 The most common adverse events that emerged during treatment
22 eceiving sirukumab including those reassigned from placebo,
the most common adverse events were again injection-site eryt
23 The most common adverse events were arthralgia (12 [11%] pati
24 The most common adverse events were cough, musculoskeletal pa
25 The most common adverse events were diarrhoea (eight [12%] of
26 The most common adverse events were diarrhoea (in 160 [85%] o
27 The most common adverse events were fatigue (25%), headache (
28 The most common adverse events were fatigue (51%), headache (
29 The most common adverse events were fatigue (n=28 [19%]) and
30 The most common adverse events were fatigue (seven participan
31 The most common adverse events were fatigue, diarrhea, muscle
32 The most common adverse events were gastrointestinal-related
33 The most common adverse events were headache (26% of patients
34 Most adverse events were mild in severity, and
the most common adverse events were headache (35 [21%] of 166
35 Overall,
the most common adverse events were headache (55 [23%] of 240
36 The most common adverse events were headache and nasopharyngi
37 The most common adverse events were headache, fatigue, diarrh
38 Overall,
the most common adverse events were headache, fatigue, diarrh
39 The most common adverse events were infective pulmonary exace
40 The most common adverse events were injection-site pain, fati
41 The most common adverse events were mild injection-site react
42 The most common adverse events were nasopharyngitis (18 [12%]
43 ), dapagliflozin 10 mg (n=296), and placebo (n=260) groups,
the most common adverse events were nasopharyngitis (38 [14%]
44 The most common adverse events were nasopharyngitis (90 [21%]
45 developed inhibitors to rFIXFc; in the 30 enrolled patients
the most common adverse events were nasopharyngitis (n=7; 23%
46 The most common adverse events were nausea (21 [17%] of 122 p
47 The most common adverse events were primarily grade 1 or 2 an
48 The most common adverse events were skin reactions occurring
49 In addition to sedation and akathisia,
the most common adverse events were tremor (42 [79%] patients
50 Gastrointestinal disorders were
the most common adverse events,
with diarrhea reported in 24